SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03686085

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Effects of Prophylactic Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.

To investigate whether vaginal dinoprostone administered before intrauterine device (IUD) insertion reduces failed insertions, insertion-related complications and pain in nulliparous women.

NCT03686085 Intrauterine Device

2 Interventions

Name: Dinoprostone 3 mg

Description: 1 vaginal tablet of dinoprostone (3mg) (prostinĀ® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
Type: Drug
Group Labels: 1

dinoprostone arm

Name: placebo vaginal tablet

Description: 1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
Type: Drug
Group Labels: 1

placebo


Primary Outcomes

Description: easiness score of IUD insertion (easy\difficult-very difficult)

Measure: easiness score of IUD insertion

Time: 5 minutes

Secondary Outcomes

Description: the difference in the pain intensity scores between the study groups BY visual analog scale score then categorized to absent-mild-moderate-severe.

Measure: the difference in the pain intensity scores between the study groups

Time: 5 minutes

Purpose: Prevention

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 T380A

Effects of Prophylactic Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.. Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women. --- T380A ---

Effects of Prophylactic Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.. Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women. --- T380A --- --- T380A ---



HPO Nodes